NEWS
‘The Price of Business’: Alex Brill Talks Rising Inflation
On April 21, Alex Brill made a special appearance on “The Price of Business” radio show to talk about the sharp rise of inflation and its effects on small businesses and individuals earning low wages.
Massachusetts’s Proposed ‘Millionaires’ Tax’ Will Push up the Federal Deficit
There is a proposed tax change in Massachusetts that should have all who are interested in fiscal policy concerned. In November, Bay State voters will decide whether to adopt an amendment to the state constitution imposing a 4 percent surtax on annual taxable income above $1 million starting in 2023.
Charitable Giving is Good. Be Smart About how to Encourage It.
In 2020, Americans’ individual charitable giving reached $324 billion, a record high and a 2.2 percent increase from 2019. While the pandemic imposed great costs on our society, many households shared their resources with others, including religious, educational, and human service organizations.
MGA Report Cited in Forbes Article on Rising Prescription Drug Prices
In his Forbes article, Ike Brannon discusses the blame game being played in Washington in regards to skyrocketing drug prices. MGA’s report “Understanding Drug Rebates and Their Role in Promoting Competition” was utilized by Brannon to bolster the argument that it is the drug companies who are responsible for drug pricing.
New Report from MGA Examines Impact of Rebates on Drug Pricing, Competition
MGA has released a new report today, “Understanding Drug Rebates and Their Role in Promoting Competition,” authored by founder and CEO Alex Brill.
The Great Resignation: Alex Brill Shares Insights on i24News
A record number of people are quitting their jobs across all employment sectors. Alex Brill joins i24News to discuss what the skyrocketing quit rates means for the US economy, and when we can expect the job market to return to normal.
Patent Thickets Constrain US Biosimilars Market
Biosimilars represent a significant cost-savings opportunity in the United States because they can introduce competition for some of the most expensive and widely used prescription drugs on the market: originator biologics. Several market and regulatory barriers have slowed biosimilar market entry and uptake in the United States.
Alex Brill Talks Rising Inflation and Corporate Taxes on CNBC’s ‘Squawk Box’
On October 15th, Alex Brill made a special appearance on CNBC’s “Squawk Box” to discuss President Biden’s corporate tax increase and the effects of rising inflation on the U.S. economy.
IAM Quotes MGA Report in Article Discussing the Problem of Patent Thickets
In his article for Intellectual Asset Management (IAM), Life Sciences Reporter Adam Houldsworth discusses the weaknesses in the US patent system that enable the “thorny” problem of patent thickets. MGA’s report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was featured heavily in the article to provide evidence of the growing problem.
Alex Brill Joins Panel Discussion on Tax Policy in the Build Back Better Act
Three policy experts join Richard Rubin of The Wall Street Journal to examine the current iteration of the Build Back Better Act.
Pension Smoothing – The Budget Gimmick That Will Not Die
The bipartisan infrastructure bill approved by the Senate on August 10 includes a number of budget gimmicks that help make it look fully “paid for.” One of the gimmicks is pension smoothing, which allows private companies to make smaller contributions to their defined-benefit pension plans, thereby endangering the plans’ financial viability over time.
Alex Brill Interviewed on Future of US Biosimilars Market
In a new BioWorld article, Mari Serebrov discusses efforts by Congress to control US prescription drug prices. Interviewed for the article was MGA’s Alex Brill, who talks about the potential side effects of such efforts.
Carbon Tax vs. Corporate Tax | In 60 Seconds
Democrats want to increase the corporate tax rate, but is that the best way to generate revenue for the government? AEI’s Alex Brill discusses an alternative tax that could benefit the planet as well.
MGA’s Christy Robinson Quoted in IAM Article on Patent Thickets
In Intellectual Asset Management (IAM), Fresenius Kabi Intellectual Property Chief Rachel Moodie discusses the worsening problem of patent thickets in the U.S. biosimilars market. Featured in the article is MGA’s report on patent thickets, as well as a quote from MGA’s Christy Robinson, who voiced her concern regarding the future of the biosimilars market.
Teva Economic Impact Report
This report, from Matrix Global Advisors (MGA), highlights Teva’s impact on economies in 15 of the 60 countries in which Teva operates. These 15 countries comprise 60 percent of Teva’s total global workforce and 75 percent of revenues in 2020. MGA’s detailed impact analysis estimates that, in 2020, Teva’s local purchases and payroll supported more than 249,000 jobs across these 15 countries, contributed $52 billion to economic output, and generated $11.7 billion in labor income.
- Despite Headwinds, Biosimilars Market Is Growing in 2024
- IRS says it will deny most claims of pandemic tax credit for employers
- Trump Talks Taxes and Tariffs
- Beware the Baseline Manipulator
- Patent Thicket Déjà Vu
- Will Congress Finally Act on Patent Thickets?
- Federal Debt: The Baseline and Options for Reform
- Navigating the Upcoming Tax Cliff: Can Republicans Prevent a Tax Increase Without Adding to the Deficit?
- Current and Future State of US Biosimilars
- Trends in the US Insulin Market: New Prices, New Players, New Dynamics
